Ocuphire Pharma Results Presentation Deck

3 Agenda and Participants. First Phase 3 Trial Topline Readout as Planned in 1Q21 ● ● ● ● Topline MIRA-2 Phase 3 Clinical Trial Results for Nyxol in Reversal of Mydriasis Reversal of Mydriasis Market Opportunity Future Milestones Q&A Participants Mina Sooch, MBA, President and CEO Jay Pepose, MD, Medical Advisory Board Susan Benton, MBA, Corporate Board Member Mitch Brigell, PhD, Head of Clinical Development Charlie Hoffmann, MBA, VP of Corporate Development and Operations Amy Rabourn, MBA, VP of Finance Ocuphire PHARMA

View entire presentation